Genomic study points to new treatment approaches for advanced small-cell lung cancer

(Ohio State University Wexner Medical Center) Small-cell lung cancer (SCLC) accounts for up to 15% of lung cancer cases. SCLC initially responds well to chemotherapy, but it often recurs in a poorly understood treatment-resistant form that is usually fatal. This study identified molecular changes in four subtypes of advanced SCLC. The findings could lead to the development of new targeted therapies for advanced SCLC.